Pasam Satish Srinivas1
BACKGROUND
Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin. In 2014, the global prevalence of diabetes was estimated to be 9% among the adults above 18 yrs. of age. More than 80% of the diabetes deaths occur in low and middle income countries.
METHOD
Present study is designed to study the effects of Repaglinide on type-2 diabetes mellitus in comparison with metformin. Subjects were randomized into two groups; one group A was given metformin 500 mg OD consisting of 20 patients, other group B was given Repaglinide 0.5 mg 30 min. before food, this group also consists of 20 patients.
RESULT
Fasting plasma glucose was decreased in both the groups, but percentage reduction in postprandial glucose was significantly higher in group A.
CONCLUSION
Hyperlipidaemia is the major cardiovascular risk factor in type 2 DM. Overall change in lipid profile was better in group B than group A.